Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2938449 | 0.86 | PLA2G1B (0.47) | PLA2G1BATG4BGAAHPGDKMT2A | |
| SCHEMBL29105801 | 0.84 | ATM (0.40) | ATMPIK3CD | |
| SCHEMBL29105799 | 0.84 | ATM (0.40) | ATMPIK3CD | |
| SCHEMBL21339145 | 0.83 | CHRNB2 (0.48) | PLA2G1BATG4BATMGAAVNN1 | |
| SCHEMBL21339455 | 0.83 | CHRNB2 (0.48) | PLA2G1BATG4BATMGAAVNN1 | |
| SCHEMBL21339452 | 0.83 | CHRNB2 (0.48) | PLA2G1BATG4BATMGAAVNN1 | |
| SCHEMBL20207288 | 0.83 | CHRNB2 (0.48) | PLA2G1BATG4BATMGAAVNN1 | |
| SCHEMBL15006800 | 0.82 | DPP4 (0.38) | PLA2G1BATG4BGAAHPGDKMT2A | |
| SCHEMBL12897446 | 0.81 | — | — | |
| SCHEMBL321905 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375789-B | Antitumor compound, preparation method thereof, pharmaceutical composition and application | 北京大学第一医院 | 2025-03-21 | — | — | CN | disclosed |
| CN-116375789-A | Antitumor compound, preparation method thereof, pharmaceutical composition and application | 北京大学第一医院 | 2023-07-04 | — | — | CN | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| EP-3830080-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2021-06-09 | — | — | EP | disclosed |
| CN-111630051-A | Spirocyclic compounds of alkenes as farnesoid X receptor modulators | 百时美施贵宝公司 | 2020-09-04 | — | — | CN | disclosed |
| WO-2020025517-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | PLA2G1B 1510/4885ATG4B 1613/4885ATM 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.